Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGN NASDAQ:BBNX NYSE:BVS NASDAQ:PROF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$14.90+0.9%$11.76$9.22▼$21.00$679.15M11.97 million shs1.35 million shsBBNXBeta Bionics$16.71+10.7%$15.46$8.89▼$24.50$656.40MN/A668,671 shs551,430 shsBVSBioventus$7.34-2.5%$6.73$5.81▼$14.38$602.94M0.83397,666 shs489,396 shsPROFProfound Medical$5.54+1.7%$5.93$3.89▼$9.87$163.79M0.5223,879 shs40,532 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen+4.24%+7.35%+22.80%+25.30%+31.08%BBNXBeta Bionics+6.19%-0.66%+17.69%+9.66%+1,509,999,900.00%BVSBioventus+3.01%+3.29%+10.57%+15.14%-4.68%PROFProfound Medical-1.98%-1.09%-5.22%+20.31%-41.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXGNAxoGen2.8851 of 5 stars3.52.00.00.03.22.50.6BBNXBeta Bionics2.7979 of 5 stars4.40.00.00.03.30.80.0BVSBioventus2.973 of 5 stars3.40.00.00.01.83.31.3PROFProfound Medical2.5108 of 5 stars3.51.00.00.02.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 3.00Buy$26.0074.50% UpsideBBNXBeta Bionics 2.75Moderate Buy$22.5634.98% UpsideBVSBioventus 2.75Moderate Buy$13.7587.33% UpsidePROFProfound Medical 3.00Buy$11.0098.56% UpsideCurrent Analyst Ratings BreakdownLatest PROF, BBNX, AXGN, and BVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025BBNXBeta BionicsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $21.007/30/2025BBNXBeta BionicsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetNeutral ➝ Neutral$15.00 ➝ $17.007/7/2025BVSBioventusCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$12.006/16/2025BBNXBeta BionicsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$26.006/12/2025BBNXBeta BionicsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$30.005/30/2025BBNXBeta BionicsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$16.005/30/2025BBNXBeta BionicsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$20.00(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$187.34M3.66N/AN/A$2.44 per share6.11BBNXBeta Bionics$65.12M11.15N/AN/A$6.94 per share2.41BVSBioventus$564.14M1.07$0.58 per share12.58$2.80 per share2.62PROFProfound Medical$10.68M15.59N/AN/A$2.01 per share2.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$9.96M-$0.10N/AN/AN/A-2.29%-4.43%-2.34%N/ABBNXBeta Bionics-$54.76MN/A0.00∞N/AN/AN/AN/AN/ABVSBioventus-$156.23MN/AN/A15.96N/A-7.11%15.61%4.01%N/APROFProfound Medical-$27.82M-$1.22N/AN/AN/A-269.35%-70.41%-57.22%8/14/2025 (Estimated)Latest PROF, BBNX, AXGN, and BVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PROFProfound Medical-$0.43-$0.52-$0.09-$0.52$4.75 millionN/A7/29/2025Q2 2025BBNXBeta Bionics-$0.51-$0.39+$0.12-$0.39$19.73 million$23.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/ABBNXBeta BionicsN/AN/AN/AN/AN/ABVSBioventusN/AN/AN/AN/AN/APROFProfound MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.594.142.67BBNXBeta BionicsN/A14.6813.79BVSBioventus1.851.410.99PROFProfound Medical0.0911.3110.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%BBNXBeta BionicsN/ABVSBioventus62.94%PROFProfound Medical47.86%Insider OwnershipCompanyInsider OwnershipAXGNAxoGen2.78%BBNXBeta BionicsN/ABVSBioventus33.00%PROFProfound Medical1.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45046.01 million44.73 millionOptionableBBNXBeta Bionics29443.47 millionN/AN/ABVSBioventus1,20082.14 million54.46 millionNot OptionablePROFProfound Medical15030.05 million29.60 millionOptionablePROF, BBNX, AXGN, and BVS HeadlinesRecent News About These CompaniesProfound Medical (PROF) Aims for 75% Revenue Growth Despite Q2 Loss1 hour ago | gurufocus.comProfound Medical Corp. (PROF) Q2 2025 Earnings Call Transcript3 hours ago | seekingalpha.comProfound Medical (PROF) Reports Q2 Loss, Misses Revenue EstimatesAugust 14 at 6:21 PM | zacks.comProfound Medical Reports Q2 2025 Growth and New Innovations in Prostate TreatmentAugust 14 at 4:39 PM | tipranks.comProfound Medical Announces Second Quarter 2025 Financial ResultsAugust 14 at 4:14 PM | financialpost.comFProfound Medical Announces Second Quarter 2025 Financial ResultsAugust 14 at 4:05 PM | globenewswire.comAltium Capital Management LLC Sells 124,411 Shares of Profound Medical (NASDAQ:PROF)August 14 at 7:31 AM | marketbeat.comProfound Medical (PROF) Projected to Post Earnings on ThursdayAugust 7, 2025 | marketbeat.comProfound Medical to Announce Q2 2025 Financial ResultsJuly 24, 2025 | tipranks.comProfound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to FollowJuly 24, 2025 | financialpost.comFProfound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to FollowJuly 24, 2025 | globenewswire.com'Profound Sadness': Colleagues, Friends Mourn Beloved East End Doctor Who Died During TriathlonJuly 17, 2025 | msn.comProfound Medical Completes First Commercial BPH Treatment With New TULSA-AI Volume Reduction ModuleJune 25, 2025 | msn.com‘Profound loss’: Police recruit dies after suffering medical emergency during final fitness testJune 23, 2025 | ky3.comKWexford family with ‘profound medical needs’ removed from choice-based letting system as council accused of lacking ‘humanity’June 16, 2025 | msn.comMedical experts unveil major clues to the type of "incurable" cancer King Charles could have been diagnosed withJune 14, 2025 | skynews.com.auSPowers Health Partners With Profound Research to Expand Clinical Trial Access in Northwest IndianaJune 10, 2025 | miamiherald.comMFamed Former NFL Safety, Leonard Wheeler, Named Global Ambassador For TULSA-PRO®June 4, 2025 | financialpost.comF1 Magnificent Healthcare Stock Down 80% to Buy and Hold ForeverMay 22, 2025 | fool.caProfound Medical Corp. (NASDAQ:PROF) CEO Purchases $43,312.99 in StockMay 21, 2025 | insidertrades.comWhy Profound Medical Corp.’s (PROF) Stock Is Up 5.07%May 16, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAMD’s Results Sparked a Sell-Off—But That’s Your Buy SignalBy Thomas Hughes | August 6, 2025These 3 Stocks Could Help You Compound Wealth for Years to ComeBy Gabriel Osorio-Mazilli | July 28, 2025The 4 Dividend Stocks Smart Money Is Grabbing Right NowBy Thomas Hughes | July 24, 2025Kinder Morgan: At the Hotspot of the Natural Gas RevolutionBy Thomas Hughes | July 21, 2025AbbVie Stock Eyes Breakout as Pipeline and Profits GrowBy Chris Markoch | July 31, 2025PROF, BBNX, AXGN, and BVS Company DescriptionsAxoGen NASDAQ:AXGN$14.90 +0.14 (+0.95%) Closing price 04:00 PM EasternExtended Trading$14.89 -0.01 (-0.07%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Beta Bionics NASDAQ:BBNX$16.71 +1.61 (+10.66%) As of 04:00 PM EasternBeta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.Bioventus NYSE:BVS$7.34 -0.19 (-2.52%) Closing price 04:00 PM EasternExtended Trading$7.34 0.00 (0.00%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.Profound Medical NASDAQ:PROF$5.54 +0.09 (+1.65%) Closing price 04:00 PM EasternExtended Trading$5.50 -0.04 (-0.72%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Deere’s Sell-Off Could Be a Long-Term Buying Chance Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go? Mercury Systems Up 27%: Financials Send Investors a Clear Signal Brinker Serves Up Earnings Beat, Sidesteps Cost Pressures CAVA’s Honeymoon Ends With a 16% Stock Drop Rigetti Stock: A Long-Term Quantum Play Facing Short-Term Tests Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access